ASCENTAGE PHARMA GROUP INTERNATIONAL
Historical Data
View all| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 3, 2026 | $19.51 | $20.20 | $19.13 | $20.01 | 14.74M |
| Jul 2, 2026 | $19.94 | $20.48 | $19.28 | $19.51 | 9.33M |
| Jul 1, 2026 | $20.34 | $20.51 | $19.88 | $19.94 | 11.43M |
| Jun 30, 2026 | $20.01 | $20.46 | $19.78 | $20.34 | 13.64M |
| Jun 29, 2026 | $19.71 | $20.44 | $19.52 | $20.01 | 11.44M |
| Jun 28, 2026 | $18.93 | $19.80 | $18.59 | $19.71 | 11.73M |
| Jun 27, 2026 | $18.74 | $19.01 | $18.54 | $18.93 | 13.34M |
| Jun 26, 2026 | $18.71 | $18.91 | $18.62 | $18.74 | 8.35M |
Company Overview
ASCENTAGE PHARMA GROUP INTERNATIONAL operates in the communication services space within the Communication Services sector. The company generates the majority of its revenue from operating momentum, and has built a durable competitive position through scale, brand, and continued reinvestment. It serves customers globally and is headquartered in the United States. Reported figures on this page are generated for demonstration and are not investment advice.
Leadership
Board 13 · Independent 12 of 13| Date | Firm | Target | Rating |
|---|---|---|---|
| Jun 27 | Citi | $18.77 | Hold |
| Jun 15 | Truist Financial | $34.62 | Neutral |
| Jun 4 | Piper Sandler | $19.52 | Buy |
| May 20 | Tigress Financial | $28.68 | Hold |
| May 14 | Needham | $28.18 | Overweight |
| May 5 | Mizuho | $23.19 | Overweight |
Politician Trades
View allWhat's Happening Right Now
- Jul 20, 2026 · Financing ↗ — Ascentage Pharma set up a US$200 million Nasdaq ATM offering following an SEC shelf filing.
- Aug 24, 2026 · Earnings ↗ — An earnings call highlighted pipeline momentum for Ascentage Pharma.
- Aug 20, 2026 · Earnings ↗ — The company presented its Q2 2026 results via an earnings call presentation.
- Aug 28, 2026 · Valuation ↗ — Coverage suggested Ascentage Pharma's Hong Kong-listed shares could be 18% undervalued after half-year losses.
- Sep 11, 2026 · Price Action ↗ — AAPG shares set a new 12-month low.
Snapshot
Ascentage Pharma Group International has not filed a Form 10-K, so no audited annual financial figures—revenue, profit, or balance-sheet data—are available for the company. Recent coverage centers on pipeline updates from its H1/Q2 2026 earnings calls rather than disclosed financial results. The company recently established a US$200 million at-the-market (ATM) equity offering program following an SEC shelf filing, pointing to a need for external capital access. Share price commentary shows notable volatility, including a new 12-month low, sharp single-day swings of up to 6%, and technical analysis around key support levels near $16-18. Some coverage flags the stock as potentially undervalued following half-year losses, though no underlying loss figures are provided here.
Bottom Line
With no audited financial disclosures on file, investors must rely on pipeline narrative and technical price action rather than fundamentals to assess AAPG. The newly established $200 million ATM facility signals potential dilution risk as the company likely funds clinical-stage operations without disclosed revenue. Meanwhile, sharp share-price volatility—including a fresh 12-month low—alongside claims of undervaluation reflect a market still searching for a stable valuation anchor for this pre-revenue biotech.